1 Molecular Epidemiology, Risk Factors and Clinical Outcomes of Carbapenem- and 2 Polymyxin-Resistant Gram-negative Bacterial Infections in Pregnant Women and 3 **Infants: A Systematic Review** John Osei Sekyere^{1#} and Melese Abate Reta¹ 4 5 ¹Department of Medical Microbiology, University of Pretoria, 0084 Prinshof Pretoria, South 6 Africa 7 #Address correspondence to jod14139@gmail.com 8 Tweet: "Clonal outbreaks of carbapenem- & colistin-resistant bacteria are common in neonatal intensive care 9 units, causing very high mortalities. However, effective antibiotic therapy and infection control can prevent 10 these deaths" 11 **Highlights** 12 Carbapenems & polymyxins are last-resort antibiotics used for multidrug-resistant 13 infections 14 Resistance to these two agents are reported in infants & pregnant women 15 K. pneumoniae, E. coli, and A. baumannii are the most common pathogens 16 Carbapenem & polymyxin resistance cause outbreaks with high infant mortalities 17 Appropriate treatment & infection control can outbreaks & save lives 18 19 20 21 22

Abstract

23

24 **Background.** Carbapenems and polymyxins are last-resort antibiotics used to treat 25 multidrug-resistant bacterial infections. However, resistance is increasing, even in vulnerable 26 groups such as pregnant women and infants, for whom therapeutic options are limited. 27 **Method.** Using a diversity of databases, the literature was searched for studies investigating 28 carbapenem and polymyxin resistance in pregnant women and infants (< 5 years). 29 **Result.** A final set of 73 manuscripts were used. In almost all countries, 30 carbapenem/polymyxin-resistant Klebsiella pneumoniae, Escherichia coli, and Acinetobacter 31 baumannii infect and/or colonizes neonates and pregnant women, causing periodic outbreaks 32 with very high infant mortalities. Plasmid-borne bland, bland, bland, bland, bland, bland, bland, and 33 bla_{GES-5} and ompK35/36 downregulation in clonal strains accelerate the horizontal and 34 vertical transmission of carbapenem resistance in these pathogens. High prevalence of 35 carbapenem/polymyxin resistance and carbapenemases were present in India, China, 36 Pakistan, Thailand, Taiwan, Turkey, Egypt, Italy, USA, South Africa, Algeria, Ghana, and 37 Madagascar. Factors such as antibiotic therapy, prolonged hospitalization, invasive 38 procedures, mother/infant colonization, mechanical ventilation, low-birth weight and preterm 39 state placed infants at high risk of carbapenem/polymyxin-resistant infections. Infant 40 mortalities ranged from 0.2% to 36.8% in different countries. 41 **Conclusion.** Use of polymyxins to treat carbapenem-resistant infections is selecting for 42 resistance to both agents, restricting therapeutic options for infected infants and pregnant 43 women. However, appropriate infection control and antibiotic therapy can contain outbreaks 44 and clear these infections. Antibiotic stewardship, periodic rectal and vaginal screening, and 45 strict infection control practices in neonatal ICUs are necessary to forestall future outbreaks 46 and deaths.

- 47 **Keywords**: Carbapenem; polymyxin; colistin; carbapenemase; antibiotic resistance; pregnant
- women; infants; neonates.

Introduction

49

50 Resistance to antimicrobials remain a major challenge to public health, veterinary medicine, 51 agriculture and aquaculture globally, owing to the limited or no therapeutic option available to treat multidrug-resistant (MDR) infections ^{1–5}. To avoid depleting our antibiotics arsenals 52 53 against infectious pathogens, certain agents are reserved as last-line drugs to fight difficult-to-54 treat infections ⁶⁻⁸. Currently, carbapenems, polymyxins (colistin) and tigecycline are used as reserved agents for MDR infections 9,10. However, the continual use of carbapenems and 55 56 polymyxins to treat bacterial infections resistant to penicillins, cephalosporins, and carbapenems are increasing the rate of resistance to these last-resort antibiotics ^{2,4,9,11}. The 57 58 emergence of carbapenem- and/or polymyxin-resistant MDR infections is thus limiting therapeutic options and increasing hospital stay, healthcare costs, morbidity, and mortality ¹²-59 ¹⁴. Subsequently, the WHO has classified carbapenem-resistant Gram-negative bacteria (CR-60 GNB) as critical priority pathogens for which novel antibiotics are urgently needed ^{15,16}. 61 62 Pregnant women and infants (below 5 years old) are a vulnerable population with regards to 63 bacterial infections due to their unbalanced and less matured immune system, respectively, and the limited therapeutic options available to them ^{17–19}. Hence, the presence of MDR 64 65 carbapenem and/or polymyxin-resistant infections among pregnant women and infants make them more susceptible to the ramifications of the infection ^{13,19,20}. Whereas several studies 66 67 have reported on pregnant women colonized with CR-GNB than infected by it, there is a risk of colonized pregnant women transferring these CR-GNB to their new borns ^{19,21–24}. It is 68 69 therefore not surprising that numerous studies report on CR-GNB- and polymyxin-resistant Gram-negative bacteria (PR-GNB)-infected neonates than colonized ones ^{20,23,25,26}. Further, 70

there have been abundant reports of clonal and polyclonal CR-GNB outbreaks in neonatal intensive care units (NICUs) globally, claiming the lives of several neonates as a result 18,27-²⁹. This makes neonates more susceptible to CR-GNB and PR-GNB infections with their associated morbidity and mortality ^{17–20,30}. Notably, CR-GNB and PR-GNB carry other antibiotic resistance genes (ARGs) on mobile plasmids, transposons, integrons, integrative conjugative elements (ICE), and insertion sequences (ISs) that facilitate the horizontal transmission of these ARGs between species and clones ^{13,20,31–33}. Specifically, extended-spectrum β-lactamases (ESBLs), fluoroquinolones, aminoglycosides, tetracycline, sulphamethoxazole-trimethoprim, and macrolide ARGs are also found in CR-GNB and PR-GNB. Hence, under antibiotic selection pressure, MDR plasmids and clones proliferate, leading to outbreaks ^{10,27,34,35}. It is thus not surprising that most neonatal CRE infections occur in NICUs during clonal outbreaks in which the isolates harbour multiple ARGs on mobile plasmids ^{20,25,26,30,36,37}. Analyses of the data obtained from this study confirms this observation. Evidence before this review A thorough review of the literature showed the absence of a review addressing carbapenem and polymyxin resistance among pregnant women and neonates. Only one review addressed carbapenem-resistance among Gram-negative bacteria (GNB) in children ¹⁴ whilst another only addressed CRE-causing neonatal sepsis in China³⁸. Thus, this is the first work to systematically review and statistically analyse the literature on carbapenem and polymyxin resistance among pregnant women and infants. Literature & databases search strategy All literature published in English were searched on Medline/PubMed, Web of Science, ScienceDirect, HINARI, Cochrane library electronic databases, and Google scholar using the

71

72

73

74

75

76

77

78

79

80

81

82

83

84

85

86

87

88

89

90

91

92

93

following search words: "Gram-negative bacteria", "epidemiology", "prevalence", "incidence", "risk factors", "determinant", "associated factors", "carbapenem", "carbapenem resistance", "colistin", "polymyxin resistance", "carbapenem-resistant Gram-negative bacteria", "carbapenem resistance determinants", "carbapenem resistance genotypes", "carbapenem resistance mechanisms", "colistin resistance determinants", "colistin resistance genotypes", "colistin resistance mechanisms", "infants", "neonates", "children" and "pregnant women". These search words were further paired with each other in a factorial fashion and search strings were implemented using "AND" and "OR" Boolean operators. "OR" was used between "colistin" and "polymyxin" as in "colistin OR polymyxin". No other filters were employed and the search was carried out up to 30th September 2020. Both authors undertook the literature search, title and abstract screening and resolved outstanding discrepancies by consensus, using the inclusion and exclusion criteria.

Inclusion and exclusion criteria

All articles addressing the following were included: 1) molecular testing of carbapenem- and polymyxin (colistin)-resistant GNB isolated from pregnant women and/or infants; 2) phenotypic antimicrobial sensitivity testing (AST) of carbapenem and polymyxin (colistin)-resistant GNB isolated from pregnant women and/or infants; 3) epidemiology (incidence, prevalence, risk factors and/or clinical outcomes) of carbapenem and/or polymyxin (colistin) resistance in pregnant women and/or infants (<5 years old); 4) articles on pregnant women and infants with carbapenem or polymyxin (colistin)-resistant infections or colonization.

Articles reporting on carbapenem-and/or polymyxin (colistin)-resistant GNB isolated from non-pregnant women and/or infants greater than 5 years old were excluded.

Statistical analyses

Data on isolation country, year of isolation, carbapenem and polymyxin resistance profiles, GNB species and clones, carbapenem and polymyxin resistance mechanisms, age, sex, clinical history, colonization or infection, clinical history, previous and current medications, clinical outcomes, mortality rate and risk factors were extracted from the included articles and populated into Microsoft Excel. Further analyses were undertaken to compute isolation rates, prevalence, resistance rates, and mortality rates per country (Tables S1-S3).

Results

Included studies and samples

A total of 1427 articles were retrieved from the various databases, of which 73 studies from 28 coutries worldwide were finally included for the qualitative and quantitative analyses (Figure S1). Studies describing carbapenem resistance in infants (n = 65 studies) were from 24 countries, involved 49 154 infants (< 5 years), and resulted in the isolation of 11 441 GNB cultures with 23.3% isolation rate (Table S1). Carbapenem resistance in pregnant women (n = 7 studies) were reported from six countries among 1892 pregnant women; this resulted in 285 GNB cultures and an isolation rate of 15.1% (Table S2). Included studies on polymyxin resistance (n = 7) were mainly in infants (n = 16 556), with one being from a pregnant woman ³⁹; 1345 GNB cultures were obtained, yielding an isolation rate of 8.1% (Table S3) (Figure S2). Fifty studies on infants involved carbapenem resistance infections, 11 involved colonization by CR-GNB, and four involved both infection and colonization. At least 22 studies out of the 50 describing GNB infections in neonates involved sepsis cases (Table S1). Notably, all the studies on PR-GNB in infants also involved infection cases with no colonizations (Table S3). However, six of the seven studies on CR-GNB in pregnant women were mainly colonization

142 cases with no infections, with only one study being an infection case in the USA (Table S2). 143 There were higher GNB isolations from India, Bangladesh, Pakistan, Morocco, China, 144 Turkey, South Africa, USA, and Cambodia than from the other countries (Figure S2). 145 Species, clones, and resistance rates 146 On a per country basis, Escherichia coli, Klebsiella pneumoniae, Acinetobacter baumannii, 147 Enterobacter sp. (cloacae), and Pseudomonas aeruginosa were the most dominant species 148 causing infections or colonization in infants and pregnant women, with *Citrobacter sp.*, 149 Proteus sp., Morganella sp., Serratia sp., and Salmonella sp. being some of the less common 150 species (Figure 1). Although these species differed in terms of prevalence per country, E. 151 coli, K. pneumoniae and A. baumannii were the most common in almost all countries whilst 152 Pseudomonas aeruginosa were highly prevalent in Italy, Nepal, USA, Turkey, and Kenya. 153 The dominant clones of the various species were mainly localized within countries with few 154 clones being observed across countries. For instance, only K. pneumoniae ST11 (in India, 155 China, and multiple settings), K. pneumoniae ST15 (India, China, and Nepal), K. pneumoniae 156 ST17 (Ghana and China) were observed across countries. Relatively few studies 157 characterized the CR-GNB isolates to determine their clonality whilst others used PFGE or 158 REP-PCR, limiting an effective international clonal analyses (Figure 2). Yet, the various 159 clones identified within the countries were mostly involved in outbreaks in neonatal intensive care units (NICU) 40-45. 160 161 Carbapenem resistance among infants in the various countries were substantial, particularly 162 in India, Pakistan, China, Egypt, Taiwan, Thailand, and USA whilst polymyxin resistance 163 rate in infants was high in Thailand, India, Malaysia, and Nepal. In pregnant women, Algeria, 164 Madagascar, and Mexico recorded the highest number of CR-GNB colonizations (Figure 3).

Carbapenem & polymyxin resistance determinants

Carbapenem resistance among CR-GNB in both infants and pregnant women were mainly mediated by carbapenemases in all countries, with few reports of non-carbapenemases such as ompK35 and ompK36 porins loss (Italy), penicillin-binding protein mutations (PBP3) (Malaysia), OXA-1 β-lactamase (China), and soxS and marA efflux regulators (Malaysia), mediating carbapenem resistance. GES-5 (Poland), IMP (Japan and China), and VIM (Italy, Hungary, and Morocco) carbapenemases were mainly dominant in single or few countries or regions (such as the Mediterranean region) whilst NDM, KPC, and OXA-48-like variants were common in many countries among infants and pregnant women. Polymyxin resistance mechanisms were largely not described in the included studies, except in one study by Naha et al. (2020) in which overexpression of acrB, tolC, ramA, and soxS were found to mediate colistin resistance ³⁶ and in another study by Zeng et al. (2016) in which *mcr-1* was found in an *Enterobacter* (now *Klebsiella*) *aerogenes* isolate (Figure 3).

Risk factors and mortality rates

Risk factors associated with CR-GNB and PR-GNB infections and colonization differed slightly between countries, with factors such as previous and/or long hospitalization, previous and/or ongoing antibiotic therapy, invasive procedures such as caesarian section, intubation, and catheterization, preterm and low birth weight infants, and mechanical ventilation being common risk factors in almost all countries. Whereas PR-GNB-associated mortalities were not reported, CR-GNB-associated mortalities were above 10% in Brazil, China, Egypt, Hungary, and Thailand and noticeably lower than 10% in India, Nepal, Turkey, Pakistan, Italy, and Cambodia.

Discussion

Carbapenem- and/or polymyxin-resistant GNB are common in neonates and pregnant women in several countries as either infections or colonizations, threatening the lives of the affected patients as CR-GNB and PR-GNB are associated with longer hospitalization and higher morbidities and mortalities ^{29,46–48}. Worryingly, many of the studies involved in this review reported on clonal and polyclonal outbreaks and infections of CR-GNB or PR-GNB among neonates in NICUs or colonization of CR-GNB in pregnant women involving pathogenic GNB such as A. baumannii, E. coli, Enterobacter sp., K. pneumoniae, and P. aeruginosa (Tables S1-S3). In most of these CR-GNB, carbapenenemases, including NDM, OXA-48, KPC, VIM, IMP, and GES-5 were found on mobile plasmids within transposons, insertion sequences, and integrons. Notably, carbapenem-resistant A. baumannii, E. coli, and K. pneumoniae harbouring mobile plasmid-borne carbapenemases cause outbreaks in neonates with sepsis, pneumonia, and other infections in NICUs in several countries worldwide, resulting in very high mortalities (Table S1) ^{17,43,49–51}. For instance, carbapenem-resistant A. baumannii outbreaks were reported by Lee et al. (2018), Sultan and Seliem (2018), Indhar et al. (2017), Al-lawama et al. (2016), Thatrimontrichai et al. (2015), Kumar et al. (2014), and Tekin et al. (2013) in Taiwan, Egypt, Pakistan, Jordan, Greece, India, and Turkey respectively, killing several infants 19,51-⁵⁶. E. coli neonatal infections and outbreaks were reported in Japan with an IMP-11 carbapenemase ³⁷, in China with nine NDM-5-producing ST410 strains ⁴⁵ and NDM-5positive ST167³³, in Turkey with an OXA-48-producing strain ⁴³, and in India with NDM-1positive clonal strains from the body of infants and the ward environment ⁴². Comparatively, outbreaks in NICUs involving K. pneumoniae were globally reported, involving NICUs infections, colonizations, mobile plasmid-borne bla_{NDM}, bla_{KPC}, bla_{OXA-48}, bla_{IMP}, bla_{VIM} and bla_{GES-5} carbapenemases, and very high mortalities, making K. pneumoniae the most deadly and common neonatal MDR pathogen ^{13,18,25,27,28,31,36,40,41,43,44,49,50,57–63}

188

189

190

191

192

193

194

195

196

197

198

199

200

201

202

203

204

205

206

207

208

209

210

211

Similarly, PR-GNB infections were also common in the same species viz., A. baumannii, E. coli, K. pneumoniae, Enterobacter sp. and Pseudomonas sp., although reports on outbreaks were either associated with carbapenem resistance ^{34,36} or absent. Hence, outbreaks involving CR-GNB that were also polymyxin resistant could also be referred to as PR-GNB outbreaks, which makes such infections very difficult to manage ^{1,2,4,9}. The largest collection of PR-GNB was recorded in Malaysia from preterm infants in a NICU in 2016, eight of which were carbapenem-resistant K. pneumoniae ³⁴. A colistin-resistant C. freundii isolate was subsequently isolated from the stool of a preterm infant in the same hospital in Malaysia, suggesting the persistence of PR-GNB in that setting ⁶⁴. Naha et al. (2020) observed that overexpression of acrB, tolC, ramA, and soxS conferred colistin resistance in a carbapenemresistant K. pneumoniae ST147, which could have been the resistance mechanism in the C. freundii isolate from Malaysia ^{36,64}. Although mcr genes, and not chromosomal mutations, are the most common mechanisms mediating polymyxin resistance globally ^{1,2,4,9}, an *mcr-1* was only identified in one study (in E. aerogenes, now K. aerogenes) and interestingly, from the vaginal secretions of a pregnant woman ³⁹. Hence, vaginal swabbing could also be used to screen for CR/PR-GNB in pregnant women besides rectal swabbing as such important pathogens can be missed if they do not occur in the gut. Further, the presence of CR/PR-GNB in the vagina could explain the colonization of infants and wards with these MDR pathogens as they can pick up these bacteria during birth ^{39,42}. If gut colonization of pregnant women with CR-GNB could potentially lead to colonization and/or infection of the neonate ^{22,24,65}, then vaginal colonization could even lead to a more direct effect than gut colonization, making vaginal screening of pregnant women an important means of preventing CR/PR-GNB infections and mortalities in neonates. The means by which infants become colonized by CR/PR-GNB remains enigmatic, although direct inoculation from mothers is highly likely. Nevertheless, neonatal colonization with

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

CR/PR-GNB is not only obtained from the mother as observed by other clinicians

20,23,26,42,61,66,67 In particular, neonates can become colonized and later infected with CR/PR-GNB during antibiotic therapy ^{23,68}, long-stay in wards (NICU) with endemic CR/PR-GNB ^{42,67}, handling by healthcare workers, breastfeeding by colonized mothers, intubation, during labour or caesarian section ^{24,65,66}, mechanized ventilation, from the community ^{23,61} etc. (Tables S1-S3). To establish a direct relationship between mother and infant colonization, and with infant colonization and infection, then a clonal analyses of isolates would have to be undertaken. As yet, studies showing this clonal relationship between GNB isolates from mother and neonate, and between neonate colonization and infection, are wanting (Figure 2). Despite the larger number of studies reporting on pregnant women colonization, there are relatively few reports of pregnant women infection with CR/-PR-GNB, suggesting that colonization does not necessarily lead to infections in pregnant women or that their stronger and much developed immune system makes them less susceptible to CR/PR-GNB infections. Hence, CR/PR-GNB colonization in pregnant women is more of a risk to neonates than to the women themselves. Nevertheless, infection of pregnant women with CR/PR-GNB could complicate their pregnancies and put their lives at risk ⁴⁶. The clonality of the species infecting both pregnant women and infants were not the same, suggesting little dissemination between colonized mothers and neonates. Further, there were very few clones of K. pneumoniae that were seen in at most three countries, with almost all the reported clones of all the species being local and restricted to single hospitals and wards (Figure 2; Tables S1-S3). This demonstrates limited circulation of the same clone even within a community, ward, hospital or country.

238

239

240

241

242

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

The carbapenemases found in the CR-GNB isolates mirrored those found in the same countries and regions (Figure 4). For instance, IMP and VIM are common in Japan/China and Italy (Europe) respectively, OXA-48 is common in the mediterranean region, Middle-East and South Africa whilst KPC and NDM are globally distributed ⁶⁹. This global epidemiology of carbapenemases is reflected in the epidemiology of carbapenemases in the infants and pregnant women (Figure 4), further corroborating the localized transmission of CR-GNB in neonates. In addition, the higher prevalence of NDM, KPC, and OXA-48-like carbapenemases over VIM and IMP ⁶⁹, also reflects the global prevalence of these βlactamases in neonates (Figure 4). The carbapenemases were mainly found on mobile plasmids (IncFII, IncX₃, IncN), integrons (*IntI*1), insertion sequences (*ISK*pn7, *ISK*pn6, ISAba125, IS26) and transposons (Tn4401b), which facilitates their movement from chromosomes to plasmids, plasmids to plasmids, and between cells of the same or different species 13,20,26,31,32,36,37,42,45,60,70 Specifically, NDM-5 carbapenemases were found on IncX₃ and IncFII plasmids in K. quasipneumoniae ST476 (in Nigeria) and E. coli ST410 (in China) respectively, which were causing outbreaks in NICUs. The immediate genetic environment of the NDM-5 on these plasmids were exactly the same or similar, suggesting that same plasmids and/or clones were mediating the spread of NDM-5 within and between species ^{31,45}. The higher mobility of these carbapenemases may explain their faster dissemination between neonates in wards and hospitals during outbreaks and evinces the need to undertake molecular analyses of isolates to comprehend their epidemiology ^{1,2,4,9,69}. Not all CR-GNB isolates contained carbapenemases. Isolates without carbapenemases, but with ESBLs such as CTX-M, TEM, SHV, and OXA, coupled with the loss or downregulation of porins ompK35 and ompK36, had very high resistance to carbapenems ^{27,44,59}. In Italy, such strains resulted in mortalities as high as 28.5% ⁵⁹.

261

262

263

264

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

Prevalence of CR/PR-GNB and carbapenemases were higher in countries with higher GNB isolation rates (Figure 3-4), which is expected as most clinical investigations are undertaken in response to increasing infections or outbreaks. Further, susceptible GNB are hardly published except when they are isolated together with resistant GNB, making the literature skewed towards resistant GNB cases. Higher reports of carbapenemases were observed in China, India, Ghana, Italy, Hungary, Turkey, South Africa, Algeria and Madagascar (in pregnant women), which does not fully reflect the carbapenem resistance rates shown in Figure 3 as not all studies investigated the underlying carbapenem resistance mechanism. For instance, Cambodia, Egypt, Greece, Pakistan, Taiwan, Thailand, and USA had higher resistance rates, but very few or no report of carbapenemases. Whereas this may be due to financial limitations in low- and middle-income countries (LMICs), the same can not be true of wealthier countries such as Taiwan, Thailand, and the USA. Hence, there is the need for increasing awareness among clinicians and researchers on the need to undertake advanced genomics analyses of resistant GNB to facilitate epidemiological analyses and interventions. On the other hand, countries with higher prevalence of carbapenemases and carbepnem resistance rates should immediately institute effective infection control and prevention practices as sufficient evidence indicates that this can both prevent and contain CR/PR-GNB outbreaks ^{41,63}. Particularly, the nosocomial colonization of neonates with clonally related carbapenemase-producing P. aeruginosa in a NICU and the subsequent isolation of a VIM-14 carbapenemase in the same pathogen in a NICU, both in Italy ^{71,72}, depict the endemic presence of this carbapenemase-producing pathogen within those periods in the affected regions. This signals the urgency required in instituting effective interventions to clear these MDR pathogens and save further lives as outbreaks in NICUs are associated with very high mortalities ^{29,50,54}.

286

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

308

Common risk factors for getting CR/PR-GNB infections across all countries have been stated above: they include include colonization of the infant or mother with CR/PR-GNB, long-term hospitalization in NICUs, undergoing invasive procedures and previous, ongoing or longer antibiotic therapy, mechanical ventilation, preterm state, and low birth weight (Fig. 5) ^{22,55,57}. Interestingly, neonatal colonization with CR/PR-GNB during NICU stay can later result in community and nosocomial infections as described by Vergadi et al. (2017) ⁶¹. Sadly, infant mortalities from CR/PR-GNB remains substantially high in many countries, including China and Brazil (Fig. 6), albeit treatment with carbapenems (at higher doses), colistin, and tigecycline have been shown to be very efficient in clearing the infection and saving lives ^{7,10,28,45,56,73}. Instructively, Kumar et al. (2014) observed that the absence of effective treatment led to higher all-cause mortalities in neonates ⁵⁴.

Conclusion and future perspectives

Evidently, carbapenem and polymyxin resistance is common in GNB isolated from infants and pregnant women, with high resistance rates and diverse carbapenemases globally, particularly in India, China, Pakistan, Thailand, Algeria, South Africa, Turkey, Ghana, Hungary, and Italy. In almost all these countries, there were local clonal outbreaks involving *A. baumanii, E. coli, Enterobacter sp., K. pneumoniae,* and *P. aeruginosa* clones hosting mobile plasmids, integrons, insertion sequences, and transposons on which were found bla_{NDM} , bla_{KPC} , bla_{OXA-48} , bla_{IMP} , bla_{VIM} and bla_{GES-5} carbapenemases. Whereas colonization in pregnant women is a risk factor for neonatal infections and outbreaks, infections in pregnant women can complicate their pregnancies. Infection with CR/PR-GNB has been associated with very high mortality rates among infants, necessitating urgent infection control interventions to prevent further outbreaks and safeguard lives. The commonality of risk factors for getting CR/PR-GNB infections in all countries indicate that adopting a standard and strict infection control measures in all healthcare centres globally can contain these

pathogens from causing further infections. Several outbreaks have been contained with strict infection control interventions. Fortunately, treatment of CR/PR-GNB infections is possible with polymyxins, higher doses of carbapenems, tigecycline, amikacin, and avibactam/sulbactam-cephalosporin/carbapenem combinations. Such treatment protocols and medicines must be distributed to all paediatricians and enforced to reduce infant mortalities. Nevertheless caution with antibiotic therapy (stewardship) must be also advised as it is a risk factor for acquired carbapenem resistance colonization or infection. Going forward, periodic genomic (molecular) surveillance/screening of hospitals (wards) and patients must be instituted to pre-emptively identify patients with CR/PR-GNB infections or colonization. Particularly, vaginal and rectal screening of pregnant women can help in surveillance exercises. Further genomic analyses to identify the clones, plasmids, and resistance mechanisms shall inform the appropriate intevention to adopt to break the chain of transmission. **Acknowledgments**: None Funding: None **Transparency declaration:** None References 1. Osei Sekyere, J. & Reta, M. A. Genomic and Resistance Epidemiology of Gram-Negative Bacteria in Africa: a Systematic Review and Phylogenomic Analyses from a One Health Perspective. mSystems 5, (2020).2. Kopotsa, K., Mbelle, N. M. & Osei Sekyere, J. Epigenomics, Genomics, Resistome, Mobilome, Virulome and Evolutionary Phylogenomics of Carbapenem-resistant Klebsiella pneumoniae clinical strains. Microb. genomics genomics (2020). doi:10.1101/2020.06.20.20135632 3. Osei Sekyere, J. & Mensah, E. Molecular epidemiology and mechanisms of antibiotic resistance in

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

- Enterococcus spp., Staphylococcus spp., and Streptococcus spp. in Africa: a systematic review from a
- 361 One Health perspective. *Ann. N. Y. Acad. Sci.* **1465**, 29–58 (2020).
- 362 4. Osei Sekyere, J., Maningi, N. E., Modipane, L. & Mbelle, N. M. Emergence of mcr-9.1 in ESBL-
- 363 producing Clinical Enterobacteriaceae in Pretoria, South Africa: Global Evolutionary Phylogenomics,
- Resistome and Mobilome. *mSystems* **5**, e00148-20 (2020).
- 365 5. Van Boeckel, T. P. et al. Global trends in antimicrobial resistance in animals in low- and middle-income
- 366 countries. *Science* (80-.). **365**, eaaw1944 (2019).
- 367 6. Osei Sekyere, J., Govinden, U., Bester, L. A. & Essack, S. Y. Colistin and Tigecycline Resistance In
- 368 Carbapenemase-Producing Gram Negative Bacteria: Emerging Resistance Mechanisms And Detection
- 369 Methods. J. Appl. Microbiol. 121, 601–617 (2016).
- 7. Cagan, E., Kiray Bas, E. & Asker, H. S. Use of Colistin in a Neonatal Intensive Care Unit: A Cohort
- 371 Study of 65 Patients. *Med. Sci. Monit.* **23**, 548–554 (2017).
- 372 8. Osei Sekyere, J. Current State of Resistance to Antibiotics of Last-Resort in South Africa: A Review
- from a Public Health Perspective. Front. Public Heal. 4, 209 (2016).
- Mmatli, M., Mbelle, N. M., Maningi, N. E. & Osei Sekyere, J. Emerging Transcriptional and Genomic
- 375 Mechanisms Mediating Carbapenem and Polymyxin Resistance in Enterobacteriaceae□: a Systematic
- Review of Current Reports. *mSystems* **5**, (2020).
- 377 10. Almohammady, M. N., Eltahlawy, E. M. & Reda, N. M. Pattern of bacterial profile and antibiotic
- 378 susceptibility among neonatal sepsis cases at Cairo University Children Hospital. J. Taibah Univ. Med.
- 379 *Sci.* **15**, 39–47 (2020).
- 380 11. Karaaslan, A. et al. Intravenous Colistin Use for Multidrug-Resistant Gram-Negative Infections in
- 381 Pediatric Patients. *Balkan Med. J.* **33**, 627–632 (2016).
- 382 12. Mularoni, A. et al. Epidemiology and successful containment of a carbapenem-resistant
- 383 Enterobacteriaceae outbreak in a Southern Italian Transplant Institute. Transpl. Infect. Dis. 21, e13119
- 384 (2019).
- 385 13. Ahmad, N., Ali, S. M. & Khan, A. U. Molecular characterization of novel sequence type of
- 386 carbapenem-resistant New Delhi metallo-beta-lactamase-1-producing Klebsiella pneumoniae in the
- 387 neonatal intensive care unit of an Indian hospital. Int. J. Antimicrob. Agents 53, 525–529 (2019).
- 388 14. Aguilera-Alonso, D., Escosa-García, L., Saavedra-Lozano, J., Cercenado, E. & Baquero-Artigao, F.
- Carbapenem-resistant Gram-negative bacterial infections in children. Antimicrobial Agents and
- 390 *Chemotherapy* **64**, (2020).
- 391 15. Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of
- antibiotic-resistant bacteria and tuberculosis. *Lancet. Infect. Dis.* **18**, 318–327 (2018).
- 393 16. Asokan, G. V, Ramadhan, T., Ahmed, E. & Sanad, H. WHO Global Priority Pathogens List: A

- 394 Bibliometric Analysis of Medline-PubMed for Knowledge Mobilization to Infection Prevention and
- 395 Control Practices in Bahrain. *Oman Med. J.* **34**, 184–193 (2019).
- 396 17. Jajoo, M. et al. Alarming rates of antimicrobial resistance and fungal sepsis in outborn neonates in
- 397 North India. *PLoS One* **13**, e0180705 (2018).
- 398 18. Essel, V. et al. A multisectoral investigation of a neonatal unit outbreak of Klebsiella pneumoniae
- bacteraemia at a regional hospital in Gauteng Province, South Africa. South African Med. J. 110, 783–
- 400 790 (2020).
- 401 19. Thatrimontrichai, A. et al. Risk factors and outcomes of carbapenem-resistant Acinetobacter baumannii
- ventilator-associated pneumonia in the neonate: A case-case-control study. J. Infect. Chemother. 22,
- 403 444–449 (2016).
- 404 20. Ahmad, N., Khalid, S., Ali, S. M. & Khan, A. U. Occurrence of blaNDM Variants Among
- Enterobacteriaceae From a Neonatal Intensive Care Unit in a Northern India Hospital. *Front.*
- 406 *Microbiol.* **9**, 407 (2018).
- 407 21. Chabah, M. et al. Healthcare-associated infections due to carbapenemase-producing Enterobacteriaceae:
- 408 Bacteriological profile and risk factors. *Med. Mal. Infect.* **46**, 157–162 (2016).
- 409 22. Chereau, F. et al. Colonization of extended-spectrum-β-lactamase- and NDM-1-producing
- Enterobacteriaceae among pregnant women in the community in a low-income country: A potential
- reservoir for transmission of multiresistant Enterobacteriaceae to neonates. *Antimicrob. Agents*
- 412 *Chemother.* **59**, 3652–3655 (2015).
- 413 23. Clock, S. A. et al. Colonization With Antimicrobial-Resistant Gram-Negative Bacilli at Neonatal
- 414 Intensive Care Unit Discharge. **6**, 219–226 (2017).
- 415 24. Mairi, A. et al. Carbapenemase-producing Enterobacteriaceae among pregnant women and newborns in
- 416 Algeria: Prevalence, molecular characterization, maternal-neonatal transmission, and risk factors for
- 417 carriage. Am. J. Infect. Control 47, 105–108 (2019).
- 418 25. Literacka, E. et al. Spread of Klebsiella pneumoniae ST45 Producing GES-5 Carbapenemase or GES-1
- 419 Extended-Spectrum β-Lactamase in Newborns and Infants. *Antimicrobial agents and chemotherapy* **64**,
- 420 6–9 (2020).
- 421 26. Arhoune, B. et al. Rectal carriage of extended-spectrum beta-lactamase- and carbapenemase-producing
- Enterobacteriaceae among hospitalised neonates in a neonatal intensive care unit in Fez, Morocco. J.
- 423 Glob. Antimicrob. Resist. **8**, 90–96 (2017).
- Datta, S. et al. A five-year experience of carbapenem resistance in Enterobacteriaceae causing neonatal
- 425 septicaemia: predominance of NDM-1. *PLoS One* **9**, e112101 (2014).
- 426 28. Huang, X. et al. Characteristics of NDM-1-producing Klebsiella pneumoniae ST234 and ST1412
- 427 isolates spread in a neonatal unit. *BMC Microbiol.* **18**, 186 (2018).

- 428 29. Johnson, J. et al. High Burden of Bloodstream Infections Associated With Antimicrobial Resistance and
- Mortality in the Neonatal Intensive Care Unit in Pune, India. Clin. Infect. Dis. (2020).
- 430 doi:10.1093/cid/ciaa554
- 431 30. Liu, J. et al. Emergence and establishment of KPC-2-producing ST11 Klebsiella pneumoniae in a
- 432 general hospital in Shanghai, China. Eur. J. Clin. Microbiol. Infect. Dis. 37, 293–299 (2018).
- 433 31. Brinkac, L. M. et al. Emergence of New Delhi Metallo-beta-Lactamase (NDM-5) in Klebsiella
- quasipneumoniae from Neonates in a Nigerian Hospital. *mSphere* **4**, (2019).
- 435 32. Islam, M. A. et al. Occurrence and characterization of multidrug-resistant New Delhi metallo-beta-
- lactamase-1-producing bacteria isolated between 2003 and 2010 in Bangladesh. J. Med. Microbiol. 62,
- 437 62–68 (2013).
- 438 33. Zhu, Y.-Q. et al. Identification of an NDM-5-producing Escherichia coli Sequence Type 167 in a
- 439 Neonatal Patient in China. Sci. Rep. **6**, 29934 (2016).
- 440 34. Yap, P. S. X. et al. Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants
- during hospitalization in neonatal intensive care unit (NICU). Pathog. Glob. Health 110, 238–246
- 442 (2016).
- 443 35. Soo, P. et al. Intestinal carriage of multidrug-resistant gram-negative bacteria in preterm-infants during
- hospitalization in neonatal intensive care unit (NICU). Pathog. Glob. Health 110, 1–9 (2016).
- Naha, S. et al. KPC-2-producing Klebsiella pneumoniae ST147 in a neonatal unit: Clonal isolates with
- differences in colistin susceptibility attributed to AcrAB-TolC pump. Int. J. Antimicrob. Agents 55,
- 447 105903 (2020).
- 448 37. Zhao, W., Chen, G., Ito, R., Kimura, S. & Hu, Z. Identification of a plasmid-borne bla IMP-11 gene in
- clinical isolates of Escherichia coli and Klebsiella pneumoniae. 246–251 (2012).
- 450 doi:10.1099/jmm.0.035626-0
- 451 38. Ding, Y., Wang, Y., Hsia, Y., Sharland, M. & Heath, P. T. Systematic review of carbapenem-resistant
- 452 Enterobacteriaceae causing neonatal sepsis in China. Ann. Clin. Microbiol. Antimicrob. 18, 36 (2019).
- 453 39. Zeng, K.-J., Doi, Y., Patil, S., Huang, X. & Tian, G.-B. Emergence of the Plasmid-Mediated mcr-1
- 454 Gene in Colistin-Resistant Enterobacter aerogenes and Enterobacter cloacae. Antimicrob. Agents
- 455 *Chemother.* **60**, 3862–3863 (2016).
- 456 40. Zheng, R. et al. Outbreak of plasmid-mediated NDM-1-producing Klebsiella pneumoniae ST105 among
- 457 neonatal patients in Yunnan, China. Ann. Clin. Microbiol. Antimicrob. 15, 10 (2016).
- 458 41. Yu, J. et al. Nosocomial outbreak of KPC-2- and NDM-1-producing Klebsiella pneumoniae in a
- neonatal ward: a retrospective study. *BMC Infect. Dis.* **16**, 563 (2016).
- 460 42. Roy, S., Singh, A. K., Viswanathan, R., Nandy, R. K. & Basu, S. Transmission of imipenem resistance
- 461 determinants during the course of an outbreak of NDM-1 Escherichia coli in a sick newborn care unit.

- 462 2773–2780 (2011). doi:10.1093/jac/dkr376
- 463 43. Poirel, L. et al. Spread of NDM-1-producing Enterobacteriaceae in a neonatal intensive care unit,
- 464 Istanbul, Turkey. *Antimicrob Agents Chemother* AAC. 02047-13 (2014).
- 465 44. Jin, Y. et al. Outbreak of Multidrug Resistant NDM-1- Producing Klebsiella pneumoniae from a
- 466 Neonatal Unit in Shandong Province, China. 1–11 (2015). doi:10.1371/journal.pone.0119571
- 467 45. Li, J. et al. Emergence of an NDM-5-producing Escherichia coli sequence type 410 clone in infants in a
- children's hospital in China. *Infect. Drug Resist.* **13**, 703–710 (2020).
- 469 46. Khatri, A. et al. Community-Acquired Pyelonephritis in Pregnancy Caused by KPC-Producing
- 470 Klebsiella pneumoniae. *Antimicrob. Agents Chemother.* **59**, 4375–4378 (2015).
- 47. Macharashvili, N. et al. Etiology of neonatal blood stream infections in Tbilisi, Republic of Georgia. Int.
- 472 J. Infect. Dis. 13, 499–505 (2009).
- 473 48. Mairi, A., Pantel, A., Sotto, A., Lavigne, J.-P. & Touati, A. OXA-48-like carbapenemases producing
- Enterobacteriaceae in different niches. Eur. J. Clin. Microbiol. Infect. Dis. 37, 587–604 (2018).
- 475 49. Stoesser, N. et al. Genome sequencing of an extended series of NDM-producing Klebsiella pneumoniae
- isolates from neonatal infections in a Nepali hospital characterizes the extent of community- versus
- hospital-associated transmission in an endemic setting. *Antimicrob. Agents Chemother.* **58**, 7347–7357
- 478 (2014).
- 479 50. Saleem, A. F., Qamar, F. N., Shahzad, H., Qadir, M. & Zaidi, A. K. M. Trends in antibiotic
- 480 susceptibility and incidence of late-onset Klebsiella pneumoniae neonatal sepsis over a six-year period
- 481 in a neonatal intensive care unit in Karachi, Pakistan. *Int. J. Infect. Dis.* 17, e961–e965 (2013).
- 482 51. Sultan, A. M. & Seliem, W. A. Identifying risk factors for healthcare-associated infections caused by
- 483 carbapenem-resistant acinetobacter baumannii in a neonatal intensive care unit. Sultan Qaboos Univ.
- 484 *Med. J.* **18**, e75–e80 (2018).
- 485 52. Indhar, F., Durrani, M. A., Bux, A. & Sohail, M. care hospital in Karachi Carbapenemases among
- 486 Acinetobacter species isolated from NICU of a tertairy care hospital in Karachi. (2017).
- 487 53. Al-lawama, M., Aljbour, H., Tanash, A. & Badran, E. Intravenous Colistin in the treatment of
- multidrug-resistant Acinetobacter in neonates. Ann. Clin. Microbiol. Antimicrob. 15, 1–4 (2016).
- 489 54. Kumar, A., Randhawa, V. S., Nirupam, N., Rai, Y. & Saili, A. Risk factors for carbapenem-resistant
- 490 Acinetobacter baumanii blood stream infections in a neonatal intensive care unit, Delhi, India. *J. Infect*.
- 491 Dev. Ctries. 8, 1049–1054 (2014).
- 492 55. Lee, H. Y. et al. Risk factors and molecular epidemiology of Acinetobacter baumannii bacteremia in
- 493 neonates. J. Microbiol. Immunol. Infect. **51**, 367–376 (2018).
- 494 56. Tekin, R., Dal, T., Pirinccioglu, H. & Oygucu, S. E. A 4-year surveillance of Device-Associated
- 495 nosocomial infections in a neonatal intensive care unit. *Pediatr. Neonatol.* **54**, 303–308 (2013).

- 496 57. Li, P. *et al.* ST37 Klebsiella pneumoniae: development of carbapenem resistance in vivo during antimicrobial therapy in neonates. *Future Microbiol.* **12**, 891–904 (2017).
- 58. Chen, D. *et al.* Co-outbreak of multidrug resistance and a novel ST3006 Klebsiella pneumoniae in a neonatal intensive care unit: A retrospective study. *Medicine (Baltimore)*. **98**, e14285 (2019).
- 500 59. Arena, F. *et al.* Large oligoclonal outbreak due to klebsiella pneumoniae ST14 and ST26 producing the FOX-7 AmpC β-lactamase in a neonatal intensive care unit. *J. Clin. Microbiol.* **51**, 4067–4072 (2013).
- 502 60. Yu, J. *et al.* Outbreak of nosocomial NDM-1-producing Klebsiella pneumoniae ST1419 in a neonatal unit. *J. Glob. Antimicrob. Resist.* **8**, 135–139 (2017).
- 504 61. Vergadi, E., Bitsori, M., Maraki, S. & Galanakis, E. Community-onset carbapenem-resistant Klebsiella 505 pneumoniae urinary tract infections in infancy following NICU hospitalisation. *J. Pediatr. Urol.* **13**, 506 495.e1-495.e6 (2017).
- 507 62. Liu, Y. *et al.* Acquisition of carbapenem resistance in multiresistant Klebsiella pneumoniae isolates of sequence type 11 at a university hospital in China. *Diagn. Microbiol. Infect. Dis.* **76**, 241–243 (2013).
- 509 63. Kong, Z. *et al.* First reported nosocomial outbreak of NDM-5-producing Klebsiella pneumoniae in a neonatal unit in China. *Infect. Drug Resist.* **12**, 3557–3566 (2019).
- 511 64. Yap, P. S. X., Ahmad Kamar, A., Chong, C. W., Yap, I. K. S. & Teh, C. S. J. Whole genome analysis of multidrug resistant Citrobacter freundii B9-C2 isolated from preterm neonate's stool in the first week. *J. Glob. Antimicrob. Resist.* 21, 246–251 (2020).
- 514 65. Rawstron, S. A. *et al.* Perirectal Screening for Carbapenem-Resistant Enterobacteriaceae Obtained From 100 Consecutive Healthy Pregnant Women in Labor at a Brooklyn Hospital: Results and Risk Factors.

 516 *Infect. Control Hosp. Epidemiol.* **39**, 369–371 (2018).
- Kothari, C. *et al.* Community acquisition of beta-lactamase producing Enterobacteriaceae in neonatal gut. *BMC Microbiol.* **13**, 136 (2013).
- Turner, P., Neou, L. & Turner, C. High Prevalence of Antimicrobial-resistant Gram-negative
 Colonization in Hospitalized Cambodian Infants. 35, 856–861 (2016).
- 521 68. Zhu, J. *et al.* Klebsiella pneumoniae: Development of carbapenem resistance due to acquisition of blaNDM-1 during antimicrobial therapy in twin infants with pneumonia. *Front. Microbiol.* **6**, 1–5 (2015).
- 524 69. Kopotsa, K., Osei Sekyere, J. & Mbelle, N. M. Plasmid evolution in carbapenemase-producing Enterobacteriaceae: a review. *Ann. New* **1457**, 61–91 (2019).
- 526 70. Xu, J., Lin, W., Chen, Y. & He, F. Characterization of an imp-4-producing klebsiella pneumoniae 527 st1873 strain recovered from an infant with a bloodstream infection in china. *Infect. Drug Resist.* **13**, 528 773–779 (2020).
- 529 71. Mammina, C. *et al.* Nosocomial colonization due to imipenem-resistant Pseudomonas aeruginosa

epidemiologically linked to breast milk feeding in a neonatal intensive care unit. 29, 1486–1492 (2008). 72. Mazzariol, A. et al. A novel VIM-type metallo-beta-lactamase (VIM-14) in a Pseudomonas aeruginosa clinical isolate from a neonatal intensive care unit. Clin. Microbiol. Infect. 17, 722–724 (2011). 73. Choudhry, S., Ahmad, E., Batool, A. & Raja, N. Use of colistin for the treatment of multi drug resistant isolates in neonates. 67, 1157–1160 (2017). Figure 1. Count and isolation rates of Gram-negative bacterial species obtained from pregnant women and infants per country. A-D shows the count and isolation rates of carbapenem-resistant Gram-negative bacteria isolated from infants per country, E shows the count and isolation rates of CR-GNB in pregnant women whilst F shows the count of polymyxin-resistant GNB in infants. Figure 2. Count of Gram-negative bacteria clones infecting or colonizing infants and **pregnant women per country. A-B** shows count and prevalence of clones isolated from infants and C shows clones isolated from pregnant women. Figure 3. Carbapenem and polymyxin resistance rates in Gram-negative bacteria isolated from infants and pregnant women. A and B show carbapenem resistance rates from infants and pregnant women respectively, and C shows polymyxin resistance rates per country. Figure 4. Carbapenemases detected in Gram-negative bacteria per country. A and B show carbapenemases detected in bacteria isolated from infants and C shows carbapenemases obtained from pregnant women. Figure 5. Risk factors associated with carbapenem and polymyxin-resistant Gramnegative bacteria in neonates and pregnant women. A-C depict risks associated with carbapenem resistance in neonates, **D** depict risks associated with carbapenem resistance in

530

531

532

533

534

535

536

537

538

539

540

541

542

543

544

545

546

547

548

549

550

551

552

pregnant women, and E depicts risks associated with polymyxin/colistin resistance in neonates and pregnant women. Figure 6. Mortality rates associated with carbapenem resistance in infants per country. Figure S1. Literature search strategy, inclusion and exclusion criteria employed to arrive at the articles used in this study. Figure S2. Isolation rate of Gram-negative bacterial species obtained from infants and pregnant women per country. A shows the isolation rate of Gram-negative bacteria obtained from infants per country, **B** shows the isolation rate of Gram-negative bacteria obtained from pregnant women per country, and C shows the isolation rate of polymyxinresistant Gram-negative bacteria obtained from infants per country, **Supplemental Table 1.** Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria infecting or colonizing infants. Supplemental Table 2. Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms, resistance rates, and prevalence of carbapenem-resistant Gram-negative bacteria infecting or colonizing pregnant women. Supplemental Table 3. Data on the epidemiology, risk factors, clinical outcomes, resistance mechanisms, resistance rates, and prevalence of polymyxin-resistant Gram-negative bacteria infecting or colonizing infants and pregnant women.

554

555

556

557

558

559

560

561

562

563

564

565

566

567

568

569


570


571

572












Carbapenem resistance-associated infant mortality rates (%) per country






Figure S1: Flow diagram showing the results of the literature and database search strategy, inclusion, and exclusion criteria, with reasons.

